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ABSTRACT 
 
Eighteen Quarter Horses were utilized in a randomized complete design for a    
28 d experiment to evaluate age-related effects on inflammation and cartilage turnover 
after induction of a single inflammatory insult using lipopolysaccharide (LPS).  Horses 
were grouped by age, with yearlings (yearling; n = 3 males, n = 3 females), 2 to 3 yr olds 
(2/3; n = 2 males, n = 4 females), and mature 5 to 8 yr olds (mature; n = 2 males, n = 4 
females).  On d 0, all horses were housed individually and fed diets that met or exceeded 
NRC (2007) requirements.  On d 14, horses were challenged with an intra-articular 
injection of LPS.  Carpal joints were randomly assigned to receive 0.5 ng LPS solution 
obtained from E. coli O55:B5, or 0.8mL sterile lactated Ringer’s solution as a 
contralateral control.  Synovial fluid was collected prior to LPS injection at pre-injection 
h 0 (PIH 0) and 6, 12, 24, 168, and 336 h post-injection.  Samples were later analyzed 
using commercial ELISA kits for prostaglandin E2 (PGE2), collagenase cleavage 
neoepitope (C2C), and carboxypropeptide of type II collagen (CPII).  Heart rate (HR), 
respiratory rate (RR), and rectal temperature (RT) were monitored over the first 24 h and 
carpal circumference and surface temperature were recorded with additional 
measurements at 168 and 336 h.  Data were analyzed using PROC MIXED procedure of 
SAS.   
Values for RT, HR, and RR were within normal range.  HR and RT were 
influenced by age (P < 0.01), while RR was unaffected by age (P ≤ 0.21).  Joint 
circumference was not influenced by age (P = 0.84), but circumference and surface 
 iii  
temperature increased (P < 0.01) over time across all age groups.  Synovial PGE2 
concentrations tended (P = 0.09) to be influenced by age with yearlings having lower (P 
= 0.03) concentrations than mature horses.  Synovial C2C concentrations were affected 
by age with yearlings and 2/3 yr olds having lower (P < 0.01) concentrations than 
mature horses.  Concentrations of synovial CPII were influenced by age with yearlings 
and 2/3 yr old having lower (P ≤ 0.02) concentrations than mature horses.  Ratios of 
CPII:C2C were influenced by age with mature and 2/3 yr old horses having increased (P 
< 0.01) values compared to yearlings.  These results indicate that inflammation and 
corresponding cartilage turnover in response to LPS administration vary with age.  
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CHAPTER I 
INTRODUCTION 
 
Osteoarthritis (OA) is one of the most significant causes of lameness and 
decreased performance that often leads to early retirement of the equine athlete 
(Todhunter and Lust, 1990).  Surveys estimate that up to 60% of lameness is related to 
OA (Caron and Genovese, 2003).  In young horses, adaptation of bone and soft tissue 
occurs during growth and training, potentially leading to the overproduction of 
inflammatory mediators, including interleukins and prostaglandins, and the enzymatic 
breakdown of the articular cartilage (Brama et al., 1998; Kidd et al., 2001; Lucia et al., 
2013).  A metabolic shift toward synthesis takes place in the young equine model, 
serving to mend damage to the cartilage framework (Lucia et al., 2013).  This response 
is not as well understood in skeletally mature horses, although it has been speculated that 
the process of cartilage turnover takes place at a much slower rate (Todhunter, 1996).  
While mature horses may be common subjects for the development of OA, it is probable 
that the disease process begins during skeletal immaturity with overloading during early 
training and exercise.  Therefore, there may be differences in inflammation and cartilage 
metabolism responses between horses of varying age.       
Lipopolysaccharide (LPS) is an established model of inflammation that is 
transient, local and repeatable.  Various studies have utilized this model to study 
biomarkers of inflammation and cartilage turnover using young or mature horses (de 
Grauw et al., 2009; Lucia et al., 2013).  Results showed variation across studies, which 
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may be due to differences in age of horse under investigation.  Prostaglandin E2 (PGE2), 
collagenase cleavage neoepitope (C2C) and carboxypropeptide of type II collagen (CPII) 
are examples of markers of inflammation and cartilage metabolism that have been 
shown to vary in timeline and concentration across various studies utilizing the LPS 
model in young or mature horses (de Grauw et al., 2009; Lucia et al., 2013).  While 
these differences exist, it may not be accurate to compare LPS data between studies from 
mature horses to the young, growing model.   
It is clear that OA can be life changing for the athletic horse.  Since current 
treatments focus solely on pain management and can have negative side effects, early 
preventative methods are a current focus in research.  A study utilizing horses of varying 
age, exposed to the same experimental conditions is needed to clarify the differences that 
have been observed across studies for inflammation and cartilage metabolism.  Further 
exploration could help identify an age range in which addition of preventative nutritional 
strategies or change in exercise protocol may be the most beneficial to the working 
horse.  
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CHAPTER II 
REVIEW OF THE LITERATURE  
 
Introduction 
Equine OA is a naturally occurring, progressive disease of the synovial joints that 
often leads to lameness, poor performance and early retirement of equine athletes 
(Todhunter and Lust, 1990).  The osteoarthritic joint is often characterized by damage to 
and reduction of articular cartilage matrix components, in addition to reduced joint 
function (McIlwraith, 2005).  For maintenance of a healthy joint, the processes of 
degradation and synthesis involved in cartilage metabolism are adjusted for net growth 
and remodeling.  In the osteoarthritic state, the balance of these processes is disrupted, 
resulting in a shift toward tissue degeneration (Kidd et al., 2001).  Prolonged exposure to 
inflammatory mediators and degradative enzymes with chronic inflammation 
perpetuates cartilage destruction.  The response to prolonged inflammation and cartilage 
metabolism may vary with age.  The osteoarthritic diseased state exists primarily in the 
aged horse, but the disease condition results from cartilage degradation that likely begins 
early in the training process.       
Synovial Joint Structure and Anatomy    
 The synovial joint functions to enable movement and to transfer load.  Its 
structure is designed to facilitate these two major functions.  A healthy joint relies on the 
integrity of normal anatomy and cellular function of all components.  The synovial 
membrane, synovial fluid, articular cartilage and bone make up these components and 
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are structures that contribute to the development of joint disease.  Understanding normal 
structure and function of the healthy synovial joint is helpful for a better understanding 
of what happens in a diseased state.       
The synovial membrane lines the joint cavity and is composed of two layers: the 
intima and the subintima.  The intima is an incomplete layer, one to four synoviocytes 
thick, with no basement membrane that overlies a layer of connective tissue called the 
subintima (Todhunter, 1996; Frisbie, 2006).  Synoviocytes are a unique feature of the 
membrane, which have secretory and phagocytic functions including: phagocytosis and 
synthesis of hyaluronan, interleukins, prostaglandins, and proteases, all of which 
significantly affect the state of cartilage (Goodrich and Nixon, 2006).   
The intimal layer of the synovial membrane is largely responsible for 
composition of the synovial fluid, which is a highly viscous, lubricating fluid and the 
medium through which nutrients reach articular cartilage (Todhunter, 1996).  
Hyaluronan and lubricin glycoproteins are synthesized by the synovial membrane cells 
and are secreted into the synovial fluid.  These molecules are thought to be important for 
boundary lubrication of the joint surfaces and for regulating synovial fluid composition 
by steric exclusion of larger molecules from the synovial cavity (Frisbie, 2006).   
The articular cartilage is a specialized connective tissue, elastic and compressible 
in nature, which covers opposing subchondral bone.  It functions to reduce the stress 
applied to bone and to provide the nearly frictionless movement of the joint (Frisbie, 
2006).  Within the synovial joint, when cartilage loading results in increased hydrostatic 
pressure, water is released from the extracellular matrix, contributing to lubrication of 
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the joint surfaces (Dijkgraaf et al., 1995).  Articular cartilage is avascular and 
alymphatic, depending completely upon diffusion through the cartilage matrix to and 
from the synovial fluid for nutrition and elimination of waste products (Dijkgraaf et al., 
1995).  The cartilage is also anueral, and pain perception within the synovial joints is 
dependent on nerve endings in the synovium, capsule, muscle, and subchondral bone 
(Dijkgraaf et al., 1995).  Chondrocytes, the cellular component of articular cartilage, are 
responsible for synthesis and maintenance of the extracellular matrix (Neil et al., 2005).  
During normal activity and exercise, joint loading encourages diffusion of chondrocyte 
nutrients and waste products through the matrix (Dijkgraaf et al., 1995; Todhunter, 
1996).  The extracellular matrix is composed primarily of water, collagens and 
proteoglycans, with a small percentage of glycoproteins (Fig. 1).  The biochemical 
composition of the extracellular matrix is responsible for the biomechanical features of 
the tissue, including resilience and elasticity (Dijkgraaf et al., 1995).   
Collagen fibrils are the main component of the extracellular matrix, constituting 
about 60% dry weight of hyaline cartilage and providing the fibrous, structural backbone 
to the matrix (Dijkgraaf et al., 1995; Poole et al., 2002).  The anatomical arrangement of 
collagen fibrils at various depths of cartilage provides structural support (Goodrich and 
Nixon, 2006).  The collagen network provides cartilage with flexibility and strength and 
serves to counteract the swelling pressure of hydrophobic proteoglycans (Dijkgraaf et 
al., 1995).  Collagen fibrils are more concentrated at the articular surface where they are 
required to resist tensile strain during weight bearing (Todhunter, 1996).         
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Fig. 1. Organization of the extracellular matrix components in articular cartilage. 
(Adapted from Frisbie, 2006). 
 
 
Chondrocyte produced type II collagen is the primary collagen type found in 
articular cartilage, comprising about 85 to 90% of the total collagen content (Todhunter, 
1996).  Type II collagen is a homotrimeric right-handed helix, composed of three 
identical α1(II) chains arranged in fibrils, that is thought to provide articular cartilage 
with its tensile strength (Todhunter, 1996; Frisbie, 2006).  Each α chain contains nearly 
1000 amino acid residues, and, except for the short sequences at the end of the chains, 
every third amino acid is glycine (Todhunter, 1996).  The repeating triplet of amino 
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acids can be represented by Gly-X-Y, where X and Y represent other amino acids, 22% 
of which are proline and 4-hydroxyproline, respectively (Platt, 1996). 
Fibril formation is critical for achieving the physiologic strength of the collagen 
framework (Ray et al., 1996).  Type II collagen is synthesized and secreted from the 
chondrocyte as a procollagen molecule that contains nonhelical propeptide extensions at 
the amino and carboxy terminal ends (McIlwraith, 2005).  Extracellular cleavage of 
these extensions yields the collagen molecule, with the cleaved extensions serving as 
useful markers to monitor collagen synthesis.  As collagen is synthesized, the newly 
released type II collagen molecules associate in the matrix to form the collagen fibrils by 
means of intermolecular cross-linking (Platt, 1996).  Cross-linking occurs once the basic 
fibril has been formed within the same collagen molecule and between adjacent collagen 
molecules, forming a 3-dimensional meshwork (McIlwraith, 2005).   
Conversely, during the remodeling process, when type II collagen fibrils are 
cleaved by collagenases, normally hidden epitopes are uncovered and can be quantified 
to study cartilage metabolism (Todhunter, 1996).  The helical portion of the type II 
collagen molecule can be cleaved across all three chains or in nonhelical sites (Platt, 
1996; Billinghurst, 1997).  During intrahelical cleavage, collagenases cleave the fibrillar 
type II collagen at a single site (Gly775-Leu/Ile776) within each α chain of the triple 
helical collagen molecule, about three quarters of the distance from the amino-terminal 
end of each chain (Billinghurst, 1997).  This yields both three-quarter and one-quarter 
length collagen fragments (Billinghurst, 1997).  These cleaved collagen fragments 
spontaneously denature and become susceptible to continued degradation by 
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collagenases, including MMP-1, -8, and -13, proteinases, such as MMP-3, and the 
gelatinases MMP-2 and -9 (Billinghurst, 1997).      
Proteoglycans are complex macromolecules that make up the remaining 40% of 
the matrix.  They consist of one or more glycosaminoglycan (GAG) chains covalently 
attached to a protein core (Todhunter, 1996).  Negatively charged GAG side-chains repel 
each other and draw water into the extracellular matrix, providing compressive stiffness 
(Frisbie, 2006; Goodrich and Nixon, 2006).  Aggrecan, the most abundant proteoglycan 
found in cartilage, associates with collagens and other proteoglycans, including 
hyaluronan.  Link protein simultaneously binds hyaluronan and the aggrecan monomer, 
decreasing the dissociation constant.  Hyaluronan functions to perform a space-filling or 
lubrication role within the synovial joint (Todhunter, 1996).  As many as 100 aggrecan 
monomers associate with hyaluronan in the form of large aggregates, providing 
compressive stiffness, resiliency and durability (McDonald et al., 1994).  The 
concentration of proteoglycan increases with increasing depth from the articular surface, 
most likely to resist compression (Todhunter, 1996).     
The articular cartilage extracellular matrix is a dynamic system, constantly 
exposed to catabolic and anabolic factors (Dijkgraaf et al., 1995).  In healthy cartilage, at 
each stage of development, relative rates of matrix synthesis and degradation are 
adjusted in order to achieve net growth or remodeling.  Chondrocytes, while only 
constituting a small percentage of the cartilage, maintain and turn over the entire matrix 
(Todhunter, 1996).  Dynamic load and cytokines, such as interleukins (IL) and tumor 
necrosis factor α (TNFα) have been shown to accelerate matrix turnover (Todhunter, 
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1996).  These factors influence production and activation of degradative enzymes that 
can break down the matrix.  This process is offset by the synthesis of enzyme inhibitors 
and growth factors, including insulin-like growth factor 1 (IGF-1) and transforming 
growth factor β (TGF β), that have been shown to increase the production of collagens 
and proteoglycans while reducing their degradation (Platt, 1996).  Normal degradation of 
the matrix is under tight regulation.  Matrix metalloproteinases 1 and 3 (MMP 1 and 
MMP 3), collagenase and stromelysin, respectively, degrade collagen and proteoglycan 
components of the matrix and are inhibited by tissue inhibitors of metalloproteinase 1 
and 2 (TIMP 1 and TIMP 2; Todhunter, 1996).  In normal articular cartilage, there is a 
slight excess of TIMPs over MMPs (Dean et al., 1989).  Pathologic processes, such as 
degenerative joint disease (DJD), that involve gradual deterioration of the extracellular 
matrix of articular cartilage may result from a shift in the tight regulatory control of 
chondrocyte metabolism.   
By increasing the rate of degradation and decreasing synthesis, cytokines induce 
the depletion of proteoglycan in normal cartilage (Todhunter, 1996).  Interleukin-1 (α 
and β; IL-1α and β) has been studied with regard to its effect on chondrocyte and 
synovial lining cell metabolism.  Activity of IL-1 is present in normal equine synovial 
fluid, and induction of equine articular cartilage degradation occurred when recombinant 
human IL-1 was added to explant culture (McDonald et al., 1994; May et al., 1994a).  In 
vitro studies have confirmed IL-1 as a potent stimulator of MMP secretion by 
chondrocytes in normal equine cartilage (McDonald et al., 1994).  The effects of IL-1 on 
articular cartilage metabolism can be repressed by IGF-1 and transforming growth 
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factor-β (TGF-β).  Hyaluronan has also been shown to inhibit IL-1 mediated 
proteoglycan degradation in bovine articular cartilage explants (Morris et al., 1992).  
Antagonistic effects of IL-1 on synovial lining cells may occur through the action of 
inhibitors residing in equine synovial fluid (May et al., 1994a).  
The synovial joint relies on the health of each of its components to function 
properly, with particular emphasis placed on cartilage maintenance.  In order to remodel 
and maintain articular cartilage, a certain amount of joint loading is required, which can 
be accomplished by normal activity and exercise.  However, overloading of cartilage can 
lead to overproduction and prolonged exposure to deleterious enzymes and 
inflammatory mediators.  Chronic exposure to inflammation and overloading of the 
joint, which can result from overtraining, can shift normal homeostatic processes of 
cartilage metabolism.  This response to loading and overloading for the joint varies with 
age of horse. 
Effects of Age on Articular Cartilage Metabolism  
There are few reports on the effects of ageing and maturation on healthy and 
diseased equine articular cartilage.  Adaptation of bone and soft tissue occurs during 
growth and training in the young equine model (Brama et al., 1998).  During this 
adaptation, horses experience repetitive trauma and stress to synovial joints, which can 
result in an overproduction of inflammatory mediators, eventually leading to breakdown 
of the articular cartilage (Kidd et al., 2001).  Early modifications can influence mature 
cartilage, known to have little capacity for repair and remodeling (Todhunter, 1996).  
Maroudas et al. (1992) stated that due to slow turnover of collagen in mature articular 
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cartilage, the collagen framework is laid down prior to maturity and undergoes little 
change thereafter.  This statement was supported by a later study, which demonstrated 
that enzymatic modifications of the collagen network are not affected by age after 
maturity in both human and equine articular cartilage (Brama et al., 1999).  Little and 
Ghosh (1997) hypothesized that the regional chondrocyte phenotype of mature cartilage 
results from factors such as weight-bearing and articulation, imposed on the joint 
postpartum.  If heterogeneous characteristics of the collagen network are induced by 
biomechanical loading, early changes may be decisive for the final makeup of the tissue 
and, consequently for future strength and resilience to injury. 
During periods of rapid growth, in the initial stages of life, composition of the 
extracellular matrix changes dramatically.  Brama et al. (1998) found MMP activity in 
the synovial fluid of joints of juvenile horses, 5 to 11 mo in age, to be almost twice that 
of adult joints, aged 4-30, indicative of a greater matrix turnover in juvenile horses.  
With the completion of this maturation phase, the cartilage remodeling continues, but at 
a slower rate, as the need for greater tissue turnover for net growth decreases 
(Todhunter, 1996; Brama et al., 2000).  Brama et al. (2000) investigated functional 
adaptations of equine articular cartilage, and discovered that the foal is born with a 
biochemically homogeneous joint with regard to proteoglycan and collagen content, as 
well as, the posttranslational modifications of the collagen network, such as cross-
linking.  It was also determined that the content of water, DNA and GAGs declines 
significantly during maturation, while the content of collagen and hydroxylysine 
increase (Brama et al., 2000).  The water content of articular cartilage has been shown to 
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decrease with age in numerous species, including horses (Kempson, 1980; Todhunter, 
1996).  Decreases in DNA content have also been shown in other species, verifying 
cellular density of articular cartilage declines with age up to the time of skeletal maturity 
(Stockwell, 1971; Igarashi and Hayashi, 1980).  
With increasing age, composition of the extracellular matrix changes and this is 
accompanied by reduced sensitivity of chondrocytes to cytokines, demonstrated by 
McDonald et al. (1994) using recombinant human IL-1 (Todhunter, 1996).  Results 
showed increased GAG synthesis in cartilage explants from young horses, aged 11 mo to 
1 yr, in response to recombinant human IL-1 exposure.  It was also shown that for a 
given increase in IL-1 dose, the change in GAG synthesis was greater for cartilage from 
young horses than mature horses.  Fubini et al. (1993) concluded similar results in vivo, 
demonstrating an age-effect response on equine articular cartilage injected with the 
corticosteroid methylprednisolone acetate.  Younger ponies, aged less than 10 yr, 
showed more severe depletion of proteoglycan than older ponies, aged greater than 10 
yr, signifying decreased chondrocyte responsiveness as horses age.  Therefore, 
depending on the age under investigation, healing and restoration of articular cartilage 
will vary.  
According to the available research, it appears that the composition and 
responsiveness of equine articular cartilage changes with age.  The processes of 
degradation and synthesis involved in cartilage metabolism differ depending on the age 
of horse, with younger, growing horses experiencing a metabolic shift toward synthesis 
to achieve net cartilage synthesis.  While this continues in the mature horse, it does so at 
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a much slower rate.  Although normal articular cartilage metabolism seems to vary 
among immature and mature horses, differences may also exist when the natural balance 
of degradation and synthesis is disrupted in a diseased state.  
Joint Disease in Horses 
 The term OA is a broad description of a group of disorders characterized by 
varying degrees of articular cartilage deterioration, often accompanied by changes in the 
bone and soft tissue (Todhunter, 1996).  Factors associated with the pathogenesis of OA 
include age, genetic predisposition, and excessive mechanical loading of the joint 
(Briston et al., 2009).  Clinical manifestation mostly commonly involves a slowly 
progressive lameness with probable joint pain, decreased range of motion and variable 
joint effusion and inflammation (Kidd, et al. 2001).  Inflammation that gives rise to 
secondary synovitis within the synovial lining and joint capsule usually manifests later 
from irritation due to the release of articular cartilage degradation products (Briston et 
al., 2009).  Within a diseased joint there is a disturbance in the normal balance between 
degradation and repair of articular cartilage as evidenced by net cartilage degeneration 
(Kidd et al., 2001).  The pathogenesis of OA is complex and the disease can develop in a 
number of different ways.  Still, the result is consistent, often producing clinical 
symptoms of pain and lameness in the horse.   
 Inflammation as a result of repeated trauma, also termed use trauma, is common 
in the joints of athletic horses (Palmer and Bertone, 1994b; Kidd et al., 2001).  A 
common clinical characteristic in the carpal and fetlock joints of young, actively training 
racehorses, for example, is primary synovitis in the absence of articular cartilage 
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damage, defined as inflammation of the synovial membrane (McIlwraith, 2002).  
Primary synovitis occurs as a result of severe injury or inadequately treated injuries. 
With sufficient rehabilitation and rest, horses can recover.  Yet, in reality, the rest period 
is often shortened or neglected completely and horses often return to work too soon 
since it can be difficult to objectively monitor recovery.  The result is prolonged 
production and exposure to inflammatory mediators, such as IL-1 and prostaglandin E2 
(PGE2), and the subsequent release of enzymes, such as MMPs, with potential to damage 
the articular cartilage matrix.  Chronic joint inflammation may eventually result in an 
imbalance of normal articular cartilage metabolism, with an increase in matrix 
destruction, as evident by alteration in the biomechanical properties of the articular 
cartilage and resultant limitations in the athletic capabilities of the horse (Palmer and 
Bertone, 1994b).  Matrix degradation is often accompanied by an increase in the 
synthesis of type II collagen and aggrecan, however these newly synthesized molecules 
are often damaged, compromising any effective attempts at repair (Poole et al., 2002).  
Ultimately, the combination of insufficient rest and sustained work will lead to reduced 
performance and lameness.        
 Mechanical factors of joint loading play a role in the pathogenesis of OA via use 
trauma.  In the healthy joint, a certain level of joint loading is required for lubrication 
and production of the matrix components.  Through repeated loading and hyperextension 
of the limbs, the equine athlete is constantly testing the ability of the joint to withstand 
mechanical demand.  Under normal conditions, stimulation of extracellular matrix 
synthesis, namely proteoglycan, is dependent on the magnitude and duration of applied 
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load.  Strenuous exercise decreases GAG concentrations and can promote remodeling of 
the subchondral bone, decreasing the natural compressive stiffness of the articular 
cartilage (Palmer and Bertone, 1994b).  Therefore, while moderate and cyclic 
compression is beneficial, heavy and/or continuous loads can be harmful to the joints 
(Palmer and Bertone, 1996).   
 Release of cytokines and inflammatory mediators is up regulated in OA 
compared to the healthy joint.  Catabolic cytokines IL-1 and TNFα increase beyond 
normal levels, promoting production of MMPs and PGE2 and inhibiting synthesis of key 
matrix components such as aggrecan and type II collagen (Frisbie, 2006).  Bertone et al. 
(2001) found significant differences in PGE2 concentrations between normal and 
diseased joints from 89 horses aged 3 to 10 yr and subsequently described PGE2 above a 
concentration of 22.5 pg/mL as a good-excellent marker for any joint disease.  IL-1 has 
also been shown to amplify the catabolic cascade by inhibiting production of naturally 
occurring anti-arthritic molecules, including interleukin-1 receptor antagonist (IL-Ra) 
and TIMPs (Frisbie, 2006).  Anabolic cytokines such as IGF and TGF promote 
chondrocytes to synthesize proteoglycans and type II collagen (Frisbie, 2006).  Such 
molecules play a role in osteoarthritis by promoting reparative efforts in diseased joints 
(Frisbie, 2006).   
The release of cytokines and inflammatory mediators initiates action of 
deleterious enzymes that are also active in healthy joints.  The MMPs collectively 
possess the ability to degrade all major components of articular cartilage and, therefore, 
play a large role in both health and disease of the articular cartilage.  A key deleterious 
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effect of acute inflammation resides with the ability of IL-1 to encourage production and 
activation of matrix destructive MMPs.  In a diseased joint, the normal homeostasis of 
anabolic chondrocyte synthetic activity and enzymatic breakdown of the matrix is 
disrupted.  Research suggests MMPs 1 and 3 are particularly important in the 
pathogenesis of OA (Todhunter, 1996).  Brama et al. (1998) found elevated MMP 
activity in the synovial fluid of OA adult metacarpophalangeal joints compared to 
normal joints, indicative of a shift toward net degradation of tissue.       
Structural changes with OA include alterations in the articular cartilage.  Mild 
OA manifests as fibrillation of the cartilage surface with some loss of chondrocytes, 
accompanied by initial increases in the water content (Kidd et al., 2001).  As the 
collagen framework of the matrix is further disrupted, water is increasingly attracted to 
the negatively charged GAGs, causing cartilage to swell.  Eventually resistance to force 
is reduced and deep clefts develop with the progression of OA.  This process can be 
characterized microscopically by a loss of proteoglycan.  With continued damage to the 
cartilage, small pieces of cartilage and subchondral bone are released into the joint 
space, further encouraging the inflammatory cycle (Kidd et al., 2001).  
The joint capsule becomes increasingly vascular and starts to thicken in response 
to inflammation in OA.  A cyclic inflammatory cycle begins with the release of 
inflammatory mediators and cytokines, such as IL-1 and TNFα from synoviocytes and 
chondrocytes.  With the release of MMPs and cytokines the inflammatory cycle is 
perpetuated, causing hypertrophy of the synovial lining of the joint (Kidd et al., 2001).  
While the synovial membrane itself has no known role in the biomechanics of the joint, 
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injury to this area may have negative consequences for the joint.  Damage to 
synoviocytes potentially causes release of degradative enzymes and cytokines, which 
ultimately contribute to changes in the articular cartilage (Evans, 1992). 
Pain associated with OA is a common reason for the development of joint-related 
problems in the horse.  While the articular cartilage itself is aneural, surrounding tissues 
are not and have been defined as sources of pain in cases of OA (Frisbie, 2006).  Sensory 
nerves in these tissues respond to chemical mediators and mechanical stimuli.  With 
joint inflammation, local mediators are released that act on these nerves to stimulate 
activation directly or lower the threshold to other stimuli (Schaible et al., 2002; Hinz and 
Brune, 2004).  Substance P, an 11-amino acid neuropeptide, is released into the synovial 
fluid from articular type C nerve fibers, and has been suggested as a mediator 
responsible for equine articular pain (Caron, 1996; de Grauw et al., 2006). Multiple 
studies have demonstrated increased levels of synovial fluid substance P in arthritic 
versus normal equine joints (Caron et al., 1992; Kirker-Head et al., 2000).  de Grauw et 
al. (2006) found higher levels of substance P in clinically painful joints that responded 
positively to intra-articular anaesthesia (IAA), suggesting a direct role in articular 
nociception in horses.   
Prostaglandins, specifically PGE2, are also thought to play a role in pain 
associate with equine OA because of the pain relief from treatment with non-steroidal 
anti-inflammatory (NSAID) drugs (May et al., 1994b).  Elevated levels of PGE2 have 
been found in previous experiments with horses diagnosed with various types of joint 
disease when compared to sound, non-arthritic horses (May et al., 1994b; Bertone et al., 
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2001).  Researchers have concluded that PGE2 is a good indicator of joint disease and 
correlates with pain and severity of lameness. The pathological changes and clinical 
manifestations associated with equine OA vary and are often undetectable before the 
disease is well established.  Early detection is key for prevention and current research is 
focusing on methods for continued improvement in this area by studying OA in the 
horse using various models to induce experimental osteoarthritic conditions. 
Experimental Joint Disease  
A model that produces joint disease is necessary for solving important questions 
related to equine joint pathophysiology and repair.  Previous studies have utilized intra-
articular injection with cartilaginous particles or monoiodoacetate to stimulate cartilage 
destruction (Hurtig, 1988; Gustafson et al., 1992).  These models failed to provide 
information on the effects of synovial inflammation on articular cartilage in the absence 
of primary cartilage damage.  Other studies have applied more extreme techniques such 
as euthanasia or permanent mechanical alteration to the joint to mimic acute joint disease 
(Frisbie et al., 2008).  Utilization of small doses of intra-articular E. coli derived LPS, an 
integral structural component of the outer leaflet of the outer membrane of all gram-
negative bacteria, has been established as a model that mimics acute, local synovitis in 
horses and provides a method for evaluation of cartilage metabolism and inflammatory 
markers without permanent alteration to the joint (Raetz et al., 1991; Palmer and 
Bertone, 1994a).  Horses are thought to be 10 times more susceptible to LPS when 
compared to other mammals, suggesting that equine chondrocytes may also be more 
responsive to LPS (MacDonald et al., 1994).  This high level of sensitivity may 
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predispose horses to rapid cartilage breakdown when synovial joints are exposed to LPS.  
This is an important consideration for the utilization of this model to produce severe, but 
transient joint inflammation.    
The LPS endotoxin acts by reacting with receptors present on the membrane of 
target cells, resulting in release of various inflammatory mediators including cytokines 
and eicosanoids (Morris, 1991).  When interacting with the cell surface of macrophages, 
LPS activates membrane-bound phospholipase A2, liberating arachidonic acid and 
increasing its metabolism via the cyclooxygenase and lipoxygenase enzyme systems 
(Fig. 2).  This ultimately produces physiologically active eicosanoids including PGE2, a 
cyclooxygenase end product of arachidonic acid (Morris, 1991).  Previous investigators 
have used varying doses of E. coli derived LPS in the horse to produce a temporary, 
local inflammatory response similar to clinical inflammatory conditions.  Firth et al. 
(1987) utilized high doses of LPS, ranging from 25 to 45 μg, in the middle carpal joint of 
ponies to produce a severe, sterile arthritis as a model to study infectious arthritis.  All 
ponies were reported as lame within 2 h post-injection and all showed systemic signs of 
endotoxemia, including fever and depression, all of which subsided by 36 h post-
injection (Firth et al., 1987).  A decreased dosage of 3 μg/joint was used more recently to 
study the response of the antebrachiocarpal joint to a severe inflammation with respect to 
eicosanoid and cytokine production (Hawkins et al., 1993).  Injection induced signs of 
acute inflammatory arthritis, including increases in PGE2 concentration in principal  
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Fig. 2. The arachidonic acid cascade (Adapted from Caron and Genovese, 1993). 
 
 
versus control joints, yet only mild, transient discomfort and minimal systemic effect.  
Palmer and Bertone (1994a), utilizing mature horses, found LPS doses of 0.125 ng to 
5,000 ng per joint adequate to induce synovitis clinically similar to acute synovitis in the 
horse.  Synovial fluid total nucleated cell count and total protein were linearly related to 
increasing dosages of intra-articular LPS ranging from 0.125 to 0.5 ng.  Intra-articular 
LPS injections of 0.5 ng resulted in mild to moderate joint effusion without any signs of 
systemic illness, while doses greater than 0.5 ng caused fever, depression and non-
weight-bearing lameness (Palmer and Bertone, 1994a).  The 0.125 ng dose produced 
mild to moderate effusion and warmth of the injected joint, mild resistance to palpation 
and grade 2 lameness, yet in order to maintain synovitis, repeated injections were 
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performed at 48, 96 and 144 h.  Other studies since have used 0.25 ng and 0.5 ng of LPS 
to prevent the need for multiple injections.    
More recent studies have confirmed use of LPS in small doses for the induction 
of temporary, local joint inflammation.  Meulyzer et al. (2009) observed no signs of 
systemic illness in mature horses (aged 14.4 ± 2.1 yr) injected with 0.25 and 0.5 ng intra-
articular LPS into both radiocarpal joints.  Resultant pain and lameness was resolved by 
48 h post-injection.  Also using mature horses (aged 5 to 8 yr), de Grauw et al. (2009) 
found the clinical response to LPS and changes in routine synovial fluid parameters to 
closely parallel previous results reported by Meulyzer et al. (2009) and Palmer and 
Bertone (1994a).  An overt inflammatory response, prompted by 0.5 ng intra-articular 
LPS assigned to a random carpal joint, was transient and did not produce systemic signs 
of endotoxemia, confirming effects as localized and limited to the injected joint.  
Following a similar protocol to induce inflammation, Lucia et al. (2013) demonstrated 
differences in the relative time course and concentrations of cartilage and inflammatory 
mediators in the carpal joints of weanling horses (aged 184 to 327 d) injected with 0.25 
ng and 0.5 ng intra-articular LPS.  A contralateral control, injected with 0.8 mL sterile 
lactated Ringer’s solution (LRS), was utilized to establish the effects of intra-articular 
LPS compared to the effects of repeated arthrocentesis alone.  Synovial PGE2 levels 
increased in both the LPS and LRS-injected joints, yet levels were higher in response to 
0.25 and 0.5 ng intra-articular LPS, demonstrating the importance of a sham-injected 
control joint in these types of studies (Lucia et al., 2013).   
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LPS in ng quantities is an established model that can be used to study the 
inflammatory response in equine synovial joints, without permanent alteration to the 
joint.  Previous studies have utilized this model to investigate levels of PGE2, however 
other processes, including the process of cartilage metabolism in response to a single 
inflammatory insult using LPS, are also the subject of much of the current research.  
Measurement and analysis of synovial fluid biomarkers can provide valuable 
information for investigating diagnostic differences between diseased and healthy joints, 
to distinguish the degree of degradation in articular cartilage and to assess potential 
variation in these factors between horses of different ages. 
Synovial Fluid Biomarkers 
 The term biomarker is a general term used to describe direct or indirect indicators 
of abnormal tissue turnover (McIlwraith, 2005).  These markers are usually molecular 
products formed during normal metabolic processes.  However, with diseases like OA, 
when the natural balance of anabolism and catabolism is altered, concentrations of 
biomarkers may increase or decrease.  With disruption to the articular cartilage, 
biomarkers are released into the synovial fluid.  These markers can indicate repair, 
synthesis, and degradation of articular cartilage, increased bone turnover or 
inflammation, and can be used to help quantify these processes (Kidd et al., 2001).  
When comparing concentrations of biomarkers utilized across several previous studies, it 
seems there is an age related response to induced inflammation.  
 Several biomarkers have been implicated for measuring inflammation and 
cartilage metabolism.  A number of cytokines and eicosanoids can be used as indirect 
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biomarkers that are not derived primarily from the tissues that make up the joint, but 
have the potential to influence the metabolism of these tissues or the integrity of the 
matrix (McIlwraith, 2005).  Bertone et al. (2001) concluded that IL-6 is sensitive and 
specific, while TNFα and IL-1β cannot adequately detect the presence of joint disease in 
general.  van den Boom et al. (2005) observed increases in synovial fluid TNFα 2 h post 
exercise in response to exercise and repeated arthrocentesis.  However, Jouglin et al. 
(2000) found no correlation between degree of joint damage and TNFα levels.  
Conclusions have also been made about eicosanoids, including PGE2, which has been 
indicated a good to excellent marker of joint disease (Bertone et al., 2001).  Gibson et al. 
(1996) reported greater PGE2 concentrations in diseased middle carpal or 
antebrachiocarpal joints compared to control joints.  No differences were found in mean 
concentrations of other eicosanoids: prostaglandin F2α (PGF2α), 6-keto-prostaglandin F1α 
(6-keto-PGF1α), and leukotriene B4 (LTB4) (Gibson et al., 1996).  Bertone et al. (2001) 
found that concentrations of thromboxane B2 (TXB2) were actually less in severe, acute, 
and chronic joints than normal joints, and therefore only concentrations below 31.5 
pg/mL were reported as a very good predictor of joint disease.  Eicosanoids are released 
into synovial fluid with most any joint disease, with some variation among eicosanoids, 
and are therefore a more sensitive indicator of joint disease in general (Bertone et al., 
2001).           
Synovial PGE2 is an eicosanoid and mediator of local inflammation that has been 
identified as an excellent marker of OA in naturally occurring arthritis (Bertone et al., 
2001).  Eicosanoids are released into the synovial fluid with most any joint disease, and 
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are a sensitive indicator of joint disease in general.  While PGE2 is elevated with any 
joint disease, there is little information in the literature to establish normal values 
(Bertone et al., 2001).  Synovial PGE2 concentrations increase in response to intra-
articular LPS in both young and skeletally mature horses (de Grauw et al., 2009; Lucia et 
al., 2013).  Lucia et al. (2013) reported peak PGE2 values at 12 h post LPS injection in 
young horses while de Grauw et al. (2009) saw increases at 8 h post-injection in mature 
horses.  Both studies observed sharp, short-lived increases in synovial PGE2 
concentrations, yet the variations between studies may be due to differences in the age of 
horse under investigation.  
Briston et al. (2009) reported age-related differences in PGE2 synthesis by equine 
cartilage explants from 3 age groups: A (≤ 10 yr), B (11-20 yr), and C (≥ 20 yr).  
Explants from group A were the least sensitive to LPS, while explants from group C 
were the most responsive.  Increases in PGE2 concentrations were observed for aged 
horses (group C) in response to LPS concentrations of 10 μg/mL by 18 h and by 24 h 
and all subsequent times for LPS concentrations of 1.0 μg/mL.  Explants from young 
horses (group A) were resistant at all concentrations (0.1 to 100 μg/mL) and at all times 
between 12 and 48 h.  Group B horses demonstrated a strong initial response to 10 
μg/mL LPS at both 12 and 18 h, however PGE2 concentrations did not increase after this 
time.  Results from this study demonstrate increased PGE2 concentrations with age when 
exposed to LPS, and the continued release of inflammatory mediators like PGE2.  
Synovial concentrations of PGE2 and length of exposure may contribute to the activation 
of degradative pathways via chondrocytes and play a role in the progression of OA.  
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Ultimately this could lead to degenerative changes in articular cartilage in response to 
mechanical load or the enhanced degradative sensitivity in older horses (Briston et al., 
2009).     
 Cartilage metabolism can be measured using biomarkers for the degradation and 
synthesis of the two major articular cartilage components: type II collagen and 
proteoglycan.  Antibodies have been developed to identify type II collagen fragments 
that have been cleaved and/or denatured, uncovering neoepitopes that were formerly 
inaccessible (Fig. 3; Hollander et al., 1994).  Elevated levels of degraded type II collagen 
have been demonstrated in synovial fluid and serum from horses, dogs, and rabbits using 
various experimental models for OA (Billinghurst et al., 1997).  The COL2-3/4Cshort , 
also known as C1,2C, immunoassay detects collagenase-cleaved collagen fragments, but 
is not specific, detecting the degradation of both types I and II collagens (McIlwraith, 
2005).  Keratan sulphate (KS) is a specific GAG molecule found in proteoglycan 
molecules of aggrecan that has been evaluated as an indicator of cartilage turnover.  
However, in one study, synovial fluid KS concentrations were found to be less valuable 
indicators of joint disease despite findings that total sulphated GAG levels were found to 
be useful (Palmer et al., 1995).  Additionally, Frisbie et al. (1999) concluded KS to be a 
marker with little potential value in the horse.  Chondroitin sulphate (CS) is the major 
GAG of aggrecan and has proven to be a useful marker of aggrecan synthesis 
(McIlwraith, 2005).  Frisbie et al. (1999) demonstrated higher synovial fluid CS-846 
concentrations in joints with osteochondral fragmentation than in control joints, 
indicating higher re-synthesis of aggrecan in OA compared to normal joints.  The CS-
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846 epitope is found in fetal and OA cartilage, but is almost completely absent in 
healthy, mature cartilage, indicating that it may not be a reliable biomarker to measure 
the effects of age on cartilage metabolism (McIlwraith, 2005).     
 
 
 
 
 
Fig. 3. Illustration of the principle behind detecting a marker of collagen degradation.  
Specific epitopes are direct markers, but most indirect markers are also detected with 
help of antibodies. (Adapted from McIlwraith, 2005). 
 
 
 
 
 Direct biomarkers of cartilage turnover include breakdown products of type II 
collagen and proteoglycan fragments, which are liberated in increased concentrations 
into the synovial fluid (Ray et al., 1996).  Initiated by IL-1, this catabolic process in 
articular cartilage leads to the stimulated release of MMPs that have been implicated as 
useful biomarkers to monitor early OA (Brama et al., 1998; McIlwraith, 2005).  In 
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humans, total MMP activity was shown to be 136% increased in OA joints compared to 
control joints.  van den Boom et al. (2005a) found increased concentrations of equine 
synovial MMP-1 in response to inflammation as a result of repeated arthrocentesis.  In 
another study, synovial MMP activity was higher in in adult (mean age 13.4, range 4-30) 
osteoarthritic metacarpophalangeal joints than in normal joints (Brama et al., 1998).  
Results from the same study also demonstrated an age-related effect on MMP activity 
with decreased activity in normal adult metacarpophalangeal joints compared to normal 
juvenile (aged 5 to 11 mo) joints (Brama et al., 1998).  Since MMPs are essential for 
matrix turnover and because they play a key role in OA, they have the potential to act as 
useful tools to assess the status of articular cartilage.   
In healthy cartilage, rates of matrix synthesis and degradation vary depending on 
maturity and are adjusted to achieve net growth or remodeling (Todhunter, 1996).  The 
major biomarkers of collagen turnover in cartilage are epitopes of type II collagen 
(Garvican et al., 2010).  With OA, normal joint metabolism homeostasis is disrupted.  
Degradation exceeds repair and the result is a net loss of articular cartilage.  With 
continued exposure to inflammation, the reparative efforts of articular cartilage fail and 
collagen is cleaved by collagenases.  This degradative process forms tropocollagen, 
which is composed of three identical α helixes each containing an amino and a carboxy 
terminus.  Further degradation of tropocollagen by collagenases produces α chains and 
peptide fragments that expose epitopes that are normally hidden (Todhunter, 1996).  
These small peptide fragments are taken up by the chondrocytes, enter into circulation, 
and are further degraded by lysosomal enzymes or diffuse into the synovial fluid.  
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Peptide fragments can be easily measured in synovial fluid or serum and can potentially 
help identify early or subtle tissue damage.   
Type II collagen is the major component of the extracellular matrix and in OA, 
degradation of type II collagen increases (Poole et al., 2002).  Analysis of these 
breakdown product fragments can provide valuable information with regard to cartilage 
turnover.  The C2C antibody recognizes collagenase-cleaved type II collagen fragments 
Garvican et al., 2010).  The concentration of C2C increases in anterior cruciate 
transection in dogs (Matyas et al., 2004).  Chu et al. (2002) found increased synovial 
fluid C2C concentrations at 4, 8 and 16 weeks after induction of experimental arthritis 
using monopolar radiofrequency energy applied arthroscopically to the cranial cruciate 
ligament compared to normal dogs.  These findings indicate that the C2C antibody may 
serve as a useful biomarker to determine the condition of a joint, and particularly 
articular cartilage  
There are limited studies investigating effect of age on levels of synovial fluid 
C2C in horses.  However, two different studies found increased levels of catabolic C2C 
in weanling and skeletally mature horses subjected to a single inflammatory insult using 
0.5 ng LPS and a similar arthrocentesis protocol (de Grauw et al., 2009; Lucia et al., 
2013).  In young horses, C2C concentrations decreased from 0 to 6 h, but peaking at 24 
h post LPS injection (Lucia et al., 2013).  A similar rise in C2C was seen in mature 
horses, with peak values also occurring at 24 h post-injection, however, values were 2 
times greater (800 ng/mL; de Grauw et al., 2009) in mature horses than those  (400 
ng/mL; Lucia et al., 2013) observed in young horses.  While these results suggest that 
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levels of C2C are influenced by LPS injection, there also may be a varied response with 
age of horse.   
During fibril formation, carboxypropeptide of type II collagen (CPII) is 
proteolytically cleaved from the procollagen strand and, thus represents a marker of type 
II collagen synthesis (Fig. 4).  The concentration of this peptide has been directly related 
to the rate of collagen synthesis, which increases in arthritic joints (de Grauw et al., 
2006).  A metabolic shift towards cartilage synthesis that serves to mend damage to the 
collagen framework has been observed in the young equine model.  Lucia et al. (2013) 
discovered increasing concentrations of CPII with increasing dosage of intra-articular 
LPS.  Anabolic CPII was linearly influenced by treatment with the exception of 12 and 
168 h post-injection, when the 0.25 ng dosage of LPS yielded greater concentrations 
than 0.5 ng.  At 6 and 24 h, horses receiving the greatest LPS dosage had greater CPII 
concentrations than horses that received intermediate and control doses.  Since the half-
life within synovial fluid is only about 16 h, the cleaved propeptide is a good indicator of 
recent collagen synthesis (Garvican et al., 2010).  Type II procollagen is expressed at 
much lower levels in adult horses, which may have relevance to changes that occur 
naturally in the cartilage of older horses (McIlwraith, 2002). 
The CPII molecule increases in response to 0.5 ng LPS in the joints of young and 
skeletally mature horses.  Frisbie et al. (1999) found increased CPII concentrations in 
young (2 to 4 yr) exercising horses in response to osteochondral fragmentation.  Lucia et 
al. (2013) observed peak values of about 3500 ng/mL at 24 h post LPS injection in 
young horses.  These values are about 2 times lower than those observed in mature  
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Fig. 4. Type II procollagen synthesis and fibril formation, showing removal of 
propeptides as the triple helix is formed. The released propeptides form the basis of the 
carboxypropeptide of type II collagen (CPII) marker (Adapted from McIlwraith, 2005). 
 
 
 
horses by de Grauw et al. (2009) who observed an increase in CPII concentrations, 
peaking at 6000 ng/mL at 24 h and remaining elevated above baseline at 168 h post LPS 
injection.  Variation between studies indicates that there may be an effect of age and 
growth, however further studies are needed to clarify effects on the time course and 
concentration of anabolic CPII in horses across various age groups within the same 
study.  
Conclusion 
Osteoarthritis is a major concern for athletic horses of all ages.  While some 
loading is required for the maintenance of a healthy synovial joint, overloading can lead 
to degenerative changes in the articular cartilage.  Early diagnosis and prevention are 
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key and the subject of much of the current research.  In order to conduct research 
regarding OA in young horses, a model of inflammation must be used.  Previously LPS 
has been used as a model for the study of transient, local inflammation.  Biomarkers, 
which show promise for early detection of equine OA and serve as a sensitive indicator 
for experimental measurements, can be detected in synovial fluid from horses exposed to 
a single inflammatory insult using ng quantities of LPS to quantify inflammation and 
cartilage metabolism. 
Previous studies using LPS and a number of other models have used immature or 
mature horses to investigate the processes of OA.  Adaptation of bone and soft tissue 
takes place in the young equine model during growth and early training.  In comparison 
to the immature model, the response of bone and soft tissue in mature horses is 
questionable.  Comparing data across studies may not be accurate because horses may 
have been exposed to different variables.  A study using horses exposed to the same 
experimental protocol and conditions, investigating inflammation and cartilage 
metabolism to study the effects of age on these processes is needed.  Therefore, the 
objective of this study is to evaluate the influence of age on inflammation and cartilage 
metabolism in horses in response to an acute inflammatory insult using LPS.  The long-
term goal of this work will be to properly evaluate response of the equine joint, 
specifically inflammation and cartilage metabolism, to an acute inflammatory insult 
using LPS.  
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CHAPTER III 
MATERIALS AND METHODS 
 
All care, handling, and sampling of horses were approved by the Texas A&M University 
Institutional Animal Care and Use Committee (AUP #2011-170).       
Horses and Treatments 
Eighteen Quarter Horses  (n = 7 males, n = 11 females) were used in a 
randomized complete design for a 28 d experiment.  All horses were selected for age 
from the Texas A&M University herd and had no history of lameness or use of anti-
inflammatory drugs for one year prior to the experiment.  Horses were assigned to 
treatment groups according to age, with yearlings (yearling; n = 3 males; n = 3 females), 
2 to 3 yr olds (2/3; n = 2 males; n = 4 females), or skeletally mature 5 to 8 yr olds 
(mature; n = 2 males; n = 4 females).  Starting on d 0, horses were housed in individual 
3.0 × 3.0 m stalls and fed diets that met or exceeded NRC (2007) requirements for the 
age group.  Horses were fed a commercially available 14% CP sweet feed (Producer’s 
Cooperative Association, Bryan, TX) and coastal Bermuda grass hay (Cynodon 
dactylon) twice daily at 0600 and 1730 (Table 1).  They were allowed ad libitum access 
to water and provided free exercise in dry lots from 0930 to 1700.  
On d 14, horses were challenged with an intra-articular injection of LPS derived 
from Escherichia coli O55:B5 (Sigma-Aldrich, St. Louis, MO).  Intra-articular 
treatments of LPS were assigned to a randomly selected radial carpal joint with the 
remaining carpal joint serving as the contralateral control (CON).  The LPS was 
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administered at 0.5 ng as previously described by Lucia et al. (2013) using weanling 
horses.  Purified LPS was reconstituted in sterile lactated Ringer’s solution (LRS) to 
yield a stock solution of 1 mg/mL.  Serial dilutions were performed from the stock 
concentration to yield individual doses of 0.8 ml as described by de Grauw et al. (2009).  
CON joints were injected with 0.8 ml of LRS. 
 
 
 
Table 1. Nutrient analysis of diet components 
 Component 
Concentrate1 Coastal Bermudagrass Hay  
(Cynodon dactylon) 
Moisture, %   7.65   7.55 
Dry Matter, % 92.35 92.45 
Crude Protein,2 % 18.82 11.26 
ADF,2 %   9.47 33.87 
NDF,2 % 16.83 61.05 
DE,2 Mcal/kg   3.42   2.51 
EE,2 %   6.84   3.53 
Ca,2 %   1.14  0.6 
P,2 %   0.73    0.22 
K,2 %   1.35    1.12 
Mg,2 %   0.26    0.34 
114% CP sweet feed concentration (Producer’s Cooperative Association, Bryan, TX) 
2Dry matter basis 
 
 
Sample Collection  
Prior to arthrocentesis, at pre-injection h 0 (PIH 0), both carpal joints were 
clipped and aseptically prepared.  Horses were sedated using 1.5 mL Sedivet® 
(romifidine hydrochloride 1% Injection, Boehringer Ingelheim, Fremont, CA).  
Additional lip and neck twitch restraint was used when necessary.  Arthrocentesis was 
performed by veterinarians from the Texas A&M University Large Animal Clinic.  
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Treatments (0.8 mL) were administered aseptically at a location medial to the extensor 
carpi radialis tendon in the palpable depression between the radial carpal bone and the 
third carpal bone to the depth of approximately 12.7 nm to avoid unnecessary contact 
with the articular cartilage (McIlwraith and Trotter, 1996). 
Synovial fluid samples (0.5 to 5.8 mL) were collected via arthrocentesis at PIH 0 
and 6, 12, 24, 168 and 336 h post-injection and transferred into sterile, non-additive 
tubes (BD Vacutainer® Blood Serum Collection Tubes, Franklin Lakes, NJ).  Following 
collection, samples were immediately placed on ice and further divided into small 
aliquots (1.25 mL) that were stored at -20°C for later analysis.  Heart rate (HR; 
beats/min), respiratory rate (RR; breaths/min), and rectal temperature (RT; °C) were 
recorded prior to arthrocentesis at PIH 0, and 6, 12, an 24 h post-injection.  Prior to all 
sample collections, at PIH 0, and 6, 12, 24, 168, and 336 h post-injection, carpal 
circumference (cm) was measured at the level of the accessory carpal bone using a soft 
tape measure and surface temperature (°C) of each carpal joint was determined using an 
infrared camera (FLIR E60, FLIR Systems, Boston, MA).  Wall temperature was 
consistently measured to monitor ambient temperature and to provide consistent 
temperature data.  Horses were continuously monitored for signs of anaphylaxis 
throughout the first 24 hours post LPS injection. 
Synovial Fluid Analysis 
Synovial fluid samples were analyzed to determine concentrations of PGE2 using 
commercial ELISA kits (R&D Systems, Minneapolis, MN) previously validated for use 
in horses (Bertone et al., 2001; de Grauw et al., 2006).  Synovial fluid samples required a 
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1:1.5, 1:2, 1:3, 1:4 or 1:5 dilution, depending on time post-injection using the calibrator 
diluent provided in the kit.  The mean minimum detectable dose was 30.9 pg/mL.  The 
interassay coefficient of variation (cv) averaged 10.6% and the mean intraassay cv was 
6.7%.  
A commercially available ELISA kit (IBEX Pharmaceuticals Inc., Quebec, 
Montreal, Canada), previously validated for use in horses (Billinghurst et al., 2001; 
Frisbie et al., 2008), was used to measure concentrations of synovial C2C.  Standards 
were diluted following kit recommendations, and samples were diluted at a 1:4 or a 1:5 
dilution, depending on time post-injection.  Samples and standards were diluted using an 
assay buffer solution provided by the manufacturer.  The minimum detectable dose for 
C2C was 10 ng/mL.  The interassay cv averaged 2.9% and the average intraassay cv was 
4.8%.   
A commercially available ELISA kit (IBEX Pharmaceuticals Inc., Quebec, 
Montreal, Canada) with a similar protocol to the C2C ELISA kit was used to measure 
concentrations of synovial CPII.  Samples required a 1:4, 1:5, 1:6 or 1:7 dilution, 
depending on time post-injection and standards were diluted following kit 
recommendations using an assay buffer solution provided with the kit.  The minimum 
detectable dose for CPII was 50 ng/mL.  The interassay cv averaged 3.0% and the mean 
intraassay cv was 4.8%.    
Statistical Analysis 
Data were analyzed using PROC MIXED procedure of SAS (SAS Inst. Inc., 
Cary, NC). The model contained effects for age, time, knee, age by time interaction, and 
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age by time by knee interaction.  This model uses both RANDOM and REPEATED 
statements.  This covariance structure specifies a random effect of differences between 
animals and creates a correlation structure within animals that decreases with increasing 
amount of time between measurements (Littell et al., 1998).  A paired t-test was used to 
compare age groups and individual time points.  Significance differences were declared 
as P ≤ 0.05, and P ≤ 0.10 was considered a trend toward significance.  
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CHAPTER IV 
RESULTS 
 
Physical Variables 
All values for HR, RR, and RT were within normal range for each age group 
(Gore et al., 2008).  There was an age by time interaction observed for RT, with values 
for yearlings being higher (P ≤ 0.03) than 2/3 yr olds and mature horses at 0, 12 and 24 h 
post-injection (Table 2).  Both HR and RT were affected by age, regardless of time, with 
yearlings having greater (P ≤ 0.02) values (44.5 ± 0.7 beats/min; 38.1 ± 0.1°C) 
compared to 2/3 yr olds and mature horses (37.0 ± 0.7 beats/min; 37.8 ± 0.1 °C and 33.2 
± 0.7 beats/min; 37.7 ± 0.1 °C, respectively).  In addition, 2/3 yr olds had faster (P < 
0.01) HR values than mature horses.  Values for HR and RT were influenced by time (P 
< 0.01) for all horses, with peak values at 12 h post-injection (Table 2).  Peak HR and 
RT values correlated with measures of inflammation in all horses, as indicated by peak 
synovial PGE2 concentrations at 12 h post-injection. Values for RR were unaffected by 
age of horse, with no difference (P = 0.21) between age groups; however, RR tended to 
be affected by time (P = 0.07), also peaking at 12 h post-injection for all horses (Table 
2). 
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Table 2. Clinical assessment of equine vital signs following intra-articular 
lipopolysaccharide (LPS) injection. 
Measure 
Age1 
SEM 
P-Value 
Yearling  2/3 Mature  Age1 Time Age1 × Time 
HR4, beats/min 44.5 37.0 33.2 0.7  < 0.01    < 0.01 0.50 
Hour   
 02 45.3 38.0 36.7 1.6 
     63 41.3 34.7 28.7 1.6 
   123 46.7 36.3 35.3 1.6 
   243 44.7 39.0 32.0 1.6 
   RR5, breaths/min 22.2 19.7 20.0 1.0     0.21       0.07  0.15 
Hour   
02 21.0 22.3 21.3 1.7 
     63 18.7 19.0 19.7 1.7 
   123 25.0 19.7 20.0 1.7 
    243 24.0 17.7 18.7 1.7 
  RT6, °C 38.1 37.8 37.7 0.1     0.01 < 0.01 0.01 
Hour  
02 38.3 37.9 37.6 0.1 
    63 37.7 37.6 37.5 0.1 
   123 38.3 38.0 37.9 0.1 
    243 38.2 37.9 37.8 0.1 
   1Age group: yearlings (yearling; n = 6), 2 to 3 yr olds (2/3; n = 6), and skeletally 
mature 5 to 8 yr olds (Mature; n = 6). 
2Pre-injection hour: prior to intra-articular LPS injection. 
3Post-injection hour: after intra-articular LPS injection.   
4Heart rate. 
5Respiratory rate. 
6Rectal temperature. 
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There were no differences (P = 0.58) in joint circumference (cm) between LPS 
and CON knees, therefore data was combined into a single graph (Fig. 5).  Joint 
circumference was not influenced by age of horse (P = 0.84), however circumference 
increased (P < 0.01) in both LPS and CON joints for all horses over time, with peak 
values at 168 h post-injection (Fig. 5).  Joint surface temperature (°C) was not different 
(P = 0.24) in LPS and CON knees; therefore the data was combined and is shown in Fig. 
6.  There was an age by time interaction for carpal joint surface temperature that was 
evident at PIH 0, and 6, 12, 168, and 336 h post-injection, when yearlings had higher (P 
< 0.01) temperature values than mature horses (Fig. 6).  At PIH 0 and 6, 12, 24, 168 and 
336 h post-injection, yearlings had greater (P ≤ 0.05) or tended to have greater (P ≤ 
0.09) carpal surface temperatures than 2/3 yr olds (Fig. 6).  Carpal joint surface 
temperature was influenced by age, with yearlings having elevated (P < 0.01) values 
(34.7 ± 0.1 °C) compared to 2/3 yr old and mature horses at all time points (33.8 ± 0.1 
°C and 33.6 ± 0.1 °C, respectively; Fig. 6).  There was also an effect of time (P < 0.01) 
on surface temperature in LPS and CON joints, with values peaking at 6 h post-injection 
for all horses (Fig. 6).  
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Fig. 5. Carpal circumference (cm; LS mean ± SEM) in horses after intra-articular 
injection with 0.5 ng lipopolysaccharide (LPS: derived from Escherichia coli O55:B5) 
or 0.8 mL sterile lactated Ringer’s solution (CON) at 0, 6, 12, 24, 168 and 336 h post-
injection.  1Age group: yearlings (yearling; n = 6), 2 to 3 yr olds (2/3; n = 6), and 
skeletally mature 5 to 8 yr olds (Mature; n = 6).   
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Fig. 6. Carpal joint surface temperature (°C; LS mean ± SEM) in horses after intra-
articular injection with 0.5 ng lipopolysaccharide (LPS: derived from Escherichia coli 
O55:B5) or 0.8 mL sterile lactated Ringer’s solution (CON) at 0, 6, 12, 24, 168 and 336 
h post-injection.  1Age group: yearlings (yearling; n = 6), 2 to 3 yr olds (2/3; n = 6), and 
skeletally mature 5 to 8 yr olds (Mature; n = 6). *,**,***Different superscripts indicate 
differences (P ≤ 0.05) in carpal joint surface temperature among different age groups at 
specific time points post-injection. 
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Synovial Joint Inflammation  
PGE2 
Synovial PGE2 concentrations in LPS and CON joints from PIH 0, over 336 h are 
shown in Fig. 7.  Synovial PGE2 tended (P = 0.09) to be influenced by age, regardless of 
time post-injection, with yearlings having decreased (P = 0.03) concentrations (528.8 ± 
108.8 pg/mL) compared to mature horses (870.4 ± 101.3 pg/mL).  Synovial PGE2 was 
influenced by time post-injection for all horses, increasing (P < 0.01) to peak values at 
12 h post-injection and returning to baseline by 336 h post- injection (Fig. 7).  There was 
a tendency for PGE2 values to be affected by knee for all horses across time, with LPS 
injected joints tending to have higher (P = 0.06) concentrations (827.9 ± 84.5 pg/mL) 
than CON joints (590.9 ± 87.2 pg/mL).  Additionally, LPS joints had increased (P < 
0.01) concentrations of synovial PGE2 at 6 and 12 h post-injection compared to CON 
joints.  
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Fig. 7. Mean synovial fluid concentrations (pg/mL) of PGE2 in horses in the LPS knee (Panel A; 0.5 ng of intra-articular 
lipopolysaccharide derived from Escherichia coli O55:B5) and in the CON knee (Panel B; 0.8 mL of intra-articular sterile 
lactated Ringer’s solution) at 0, 6, 12, 24, 168 and 336 h post-injection.  1Age group: yearlings (yearling; n = 6), 2 to 3 yr olds 
(2/3; n = 6), and 5 to 8 yr olds (Mature; n = 6).
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Biomarkers of Cartilage Metabolism 
 
Catabolic C2C 
Synovial concentrations of catabolic C2C over 336 h in LPS and CON injected 
joints are displayed in Fig. 8.  At 6 and 168 h post-injection, yearling horses had 
decreased (P < 0.01) C2C concentrations compared to 2/3 yr olds and lower (P ≤ 0.03) 
values compared to mature horses at 6, 24, 168, and 336 h (Fig. 8).  At 12 h post-
injection 2/3 yr olds had lower (P = 0.03) concentrations of C2C than mature horses and 
tended to have decreased (P = 0.07) concentrations over mature horses at 168 h.  
Yearlings had increased (P < 0.01) levels of C2C over 2/3 yr olds and tended to have 
increased (P = 0.09) levels over mature horses at 12 h (Fig. 8).  Yearlings and 2/3 yr olds 
had lower (P < 0.01) concentrations (200.1 ± 11.0 ng/mL and 219.7 ± 11.0 ng/mL) than 
mature horses (275.1 ± 11.0 ng/mL) at all time points post-injection.  For all age groups, 
the LPS injected joint had higher (P = 0.02) concentrations (246.8 ± 9.0 ng/mL) 
compared to CON joints (216.5 ± 9.0 ng/mL).  There was an effect of time for all horses, 
with concentrations increasing (P < 0.01) to peak values at 24 h (342.6 ± 13.1 ng/mL), 
and returning to baseline by 336 h (Fig. 8).   
  45 
 
 
Fig. 8. Mean synovial fluid concentrations (ng/mL) of catabolic collagenase cleavage neoepitope of type II collagen (C2C) in 
horses in the LPS knee (Panel A; 0.5 ng of intra-articular lipopolysaccharide derived from Escherichia coli O55:B5) and in the 
CON knee (Panel B; 0.8 mL of intra-articular sterile lactated Ringer’s solution) at 0, 6, 12, 24, 168 and 336 h post-injection.  
1Age group: yearlings (yearling; n = 6), 2 to 3 yr olds (2/3; n = 6), and 5 to 8 yr olds (Mature; n = 6). a,bDifferent superscripts 
indicate differences (P ≤ 0.05) in synovial C2C concentration among different age groups at specific time points after 
injection.
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Anabolic CPII 
Synovial concentrations of anabolic CPII in LPS and CON joints from PIH 0, 
over 336 h are shown in Fig. 9.  There was an age by time interaction, most notable at 0, 
24, 168 and 336 h.  At PIH 0 and 336 h yearlings had lower (P ≤ 0.03) CPII 
concentrations than 2/3 and mature horses (Fig. 9).  Anabolic CPII levels in yearlings 
and 2/3 yr olds were lower (P < 0.01) than mature horses at 24 h post-injection, while at 
168 h yearling CPII tended to be lower (P = 0.06) than 2/3 yr olds and was decreased (P 
< 0.01) compared to mature horses (Fig. 9).  Anabolic CPII was influenced by age at all 
time points post-injection, with yearlings tending to have lower (P = 0.06) 
concentrations than 2/3 yr olds (2252.4 ± 196.4 ng/mL) and lower (P ≤ 0.02) 
concentrations (1560.3 ± 253.9 ng/mL) compared to mature horses (2891.2 ± 216.1 
ng/mL).  Anabolic CPII was affected by time, in both LPS and CON joints for all horses, 
with concentrations increasing (P ≤ 0.02) to 168 h, and returning to baseline by 336 h 
post-injection (Fig. 9).  
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Fig. 9. Mean synovial fluid concentrations (ng/mL) of anabolic carboxypropeptide of type II collagen (CPII) in horses in the 
LPS knee (Panel A; 0.5 ng of intra-articular lipopolysaccharide derived from Escherichia coli O55:B5) and in the CON knee 
(Panel B; 0.8 mL of intra-articular sterile lactated Ringer’s solution) at 0, 6, 12, 24, 168 and 336 h post-injection.  1Age group: 
yearlings (yearling; n = 6), 2 to 3 yr olds (2/3; n = 6), and 5 to 8 yr olds (Mature; n = 6). a,bDifferent superscripts indicate 
differences (P ≤ 0.05) in synovial CPII concentration among different age groups at specific time points after injection.
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CPII:C2C 
 Ratios of synovial fluid CPII to C2C concentrations in LPS and CON joints from 
PIH 0, over 336 h are shown in Fig. 10.  An age by time interaction for both LPS and 
CON knees was observed and was most notable at 6 h post-injection when yearlings 
showed higher (P = 0.04) ratio values than mature horses and at PIH 0 and 336 h post-
injection when yearling horses had lower (P < 0.01) ratio values than both 2/3 and 
mature horses (Fig. 10).  CPII:C2C was influenced by age, regardless of time post-
injection, with mature and 2/3 yr old horses having increased (P < 0.01) values 
compared to yearlings.  There was also an effect of time, with peak values for all horses 
increasing (P < 0.01) up to 336 h post-injection.     
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Fig. 10. Ratio of the mean synovial fluid concentration of carboxypropeptide of type II collagen (CPII) to the mean synovial 
fluid concentration of collagenase cleavage neoepitope of type II collagen (C2C) in horses in the LPS knee (Panel A; 0.5 ng of 
intra-articular lipopolysaccharide derived from Escherichia coli O55:B5) and in the CON knee (Panel B; 0.8 mL of intra-
articular sterile lactated Ringer’s solution) at 0, 6, 12, 24, 168 and 336 h post-injection.  1Age group: yearlings (yearling; n = 
6), 2 to 3 yr olds (2/3; n = 6), and 5 to 8 yr olds (Mature; n = 6). a,bDifferent superscripts indicate differences (P ≤ 0.05) in 
synovial CPII:C2C among different age groups at specific time points after injection. 
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CHAPTER V 
 
DISCUSSION 
  
In the current study, measurements for HR, RR, and RT were all within normal 
range for each age group.  Values for HR and RT were greater in younger horses 
compared older horses, however normal vitals are expected to be elevated in young 
horses compared to mature (Gore et al., 2008).  Additionally, HR, RR, and RT values 
peaked at 12 h post LPS injection for all horses, which corresponds to peak 
inflammation, as indicated by peak synovial PGE2 concentrations.  All vitals returned to 
baseline values by 24 h post- injection, which is most likely an indication of horses 
becoming more comfortable with handling procedures.  Clinical responses of HR, RR, 
and RT showed no signs of systemic illness and were similar to those previously 
reported in studies utilizing young or mature horses exposed to a single inflammatory 
insult using nanogram quantities of LPS (de Grauw et al., 2009; Lucia et al., 2013).  
 Joint effusion as a result of LPS-induced inflammation and/or repeated 
arthrocentesis, can lead to increased joint circumference.  Joint circumference did not 
differ between age groups, however circumference values did increase above baseline by 
168 h in all horses in response to LPS injection and repeated arthrocentesis.  This differs 
from a previous study that showed peak circumference values at 24 h post-injection 
(Lucia et al., 2013).  However, Lucia et al. (2013) only recorded circumference values 
up to 24 h post-injection, and did not report values at168 h.  In the current study, surface 
temperature of carpal joints was greater in yearlings than the 2/3 yr olds and mature 
horses.  Values peaked 6 h post-injection, prior to peak synovial PGE2 concentrations
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and decreased back to baseline by 24 h in all horses as inflammation subsided.  No 
previous studies examining the effects of an LPS challenge on carpal joint surface 
temperature have been found, therefore no comparisons can be made at this time.  
Synovial PGE2 is a mediator of inflammation that has been described as an 
excellent indicator of equine OA (Bertone et al., 2001).  Increases in synovial PGE2 have 
been demonstrated using various experimental models including exercise, osteochondral 
fragmentation, and LPS (Frisbie et al., 2008; de Grauw et al., 2009; Lucia et al., 2013).  
With experimental induction of inflammation using LPS, eicosanoid concentrations, 
including PGE2, vary depending on time post-injection.  In the current study, an 
inflammatory response was observed across age groups as indicated by increases in 
synovial PGE2 concentrations.  Synovial PGE2 tended to be greater in mature horses 
compared to yearling horses.  These results indicate an increased inflammatory response 
in older horses in response to LPS injection.  This is consistent with a previous in vitro 
study that demonstrated age-related differences in PGE2 production by equine cartilage 
explants (Briston et al., 2009).  Explants from aged horses were the most sensitive to 
LPS, producing significantly greater concentrations of PGE2, suggesting that PGE2 
concentrations increase with age (Briston et al., 2009).  Over time, with chronic 
exposure to inflammatory mediators like PGE2, degradative changes to the articular 
cartilage could result from mechanical load or an increased sensitivity to degradation in 
older horses. 
 Values for PGE2 peaked for all horses at 12 h post-injection, returning to 
baseline by 336 h, indicating a transient inflammation in response to intra-articular LPS 
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injection.  These results are consistent with a previous study that utilized 0.5 ng intra-
articular LPS to induce inflammation in weanling horses (Lucia et al., 2013).  Another 
study by de Grauw et al. (2009) also utilized 0.5 ng LPS solution and a similar 
arthrocentesis protocol in mature horses and observed sharp, short lived increases in 
synovial PGE2 at 8 h post- injection.  These peak concentrations are numerically lower 
than peak values observed at 12 h by Lucia et al. (2013) in weanling horses.  However, it 
was postulated by Lucia et al. (2013) that the delayed increase in PGE2 concentrations in 
younger horses could be a reflection of the more frequent number of samples obtained 
via arthrocentesis.  Results from the current study support this hypothesis since all age 
groups demonstrated peak PGE2 concentrations at 12 h post-injection.  Had 
measurements been taken at 12 h post-injection by de Grauw et al. (2009), elevated 
concentrations of synovial PGE2 may have been noted at that time period.  
Concentrations of PGE2 tended to be higher in LPS joints compared to CON 
joints for all horses, across all time periods.  This was most evident at 6 and 12 h post-
injection.  This demonstrates the importance of using contralateral controls for direct 
comparison of the effects of LPS injection versus arthrocentesis alone on synovial fluid 
biomarker concentrations.  van den Boom et al. (2005b) saw increases in synovial PGE2 
when arthrocentesis was performed at 12 h intervals, with concentrations remaining 
elevated through 60 h.  Frisbie et al. (2008) utilized repeated arthrocentesis in another 
study, but noted no significant effects on synovial PGE2, most likely due to 
arthrocentesis being 1 wk apart.  Data from this study and a previous study by Lucia et 
al. (2013) indicate that there is an inflammatory response from repeated arthrocentesis 
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alone.  However, this response appears to be decreased compared to LPS injection and 
the accompanying arthrocentesis protocol.   
The C2C antibody recognizes fragments of collagenase-cleaved type II collagen.  
A previous study observed increases in type II collagen degradation in response to 
exercise and joints subjected to osteochondral fragmentation (Frisbie et al., 2008).  
Increased concentrations of catabolic C2C have been observed using LPS-induced 
inflammation in both young and skeletally mature horses (de Grauw et al., 2009; Lucia 
et al., 2013).  Variation in C2C concentrations exists across studies, with peak 
concentrations at 24 h observed by de Grauw et al. (2009) in mature horses being two 
times greater than values seen by Lucia et al. (2013) in weanlings also at 24 h.  In the 
current study, peak synovial C2C values occurred at 24 h post-injection for all age 
groups.  At this time, mature horses had concentrations of synovial C2C (443.17 ± 23.46 
ng/mL) that were approximately one and a half times higher than yearling and 2/3 yr old 
horses (312.83 ± 22.40 ng/mL and 271.76 ± 22.41 ng/mL, respectively).  The results 
from the current study, in conjunction with those from previous studies, show increased 
C2C concentrations with age, indicating an increased degradative response in mature 
horses exposed to intra-articular LPS compared to younger horses.         
Synovial C2C concentrations were also elevated in LPS joints compared to CON 
joints in the current study.  An increased inflammatory response in LPS joints, as 
indicated by greater levels of synovial PGE2, can lead to cartilage breakdown.  
Degradation of the articular cartilage, quantified using concentrations of synovial C2C, 
is most likely increased in joints exposed to LPS injection rather than repeated 
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arthrocentesis alone, due to an increased inflammatory response (Garvican et al., 2010).  
Concentrations of synovial C2C have been shown to increase with joint inflammation in 
rabbits and with osteochondral injury in Thoroughbred racehorses (Kojima et al., 2001; 
Trumble et al., 2009).  Therefore, it is probable that LPS injection, which is an 
established model of experimental inflammation, has an effect on synovial C2C 
concentrations, through its ability to induce the release of inflammatory mediators such 
as PGE2, leading to the enzymatic breakdown of type II collagen (de Grauw et al., 2009; 
Lucia et al., 2013).       
Associated with the increased cleavage of collagen by collagenases is a rise in 
the synthesis of matrix molecules, including type II collagen, which is proteolytically 
cleaved from the procollagen strand during fibril formation.  Frisbie et al. (2008) 
demonstrated increased collagen synthesis with exercise and osteochondral 
fragmentation as evidenced by increased synovial fluid CPII under these conditions.  
Values for CPII have also been found to increase in response to intra-articular LPS 
injection in both growing and mature horses, with variation in concentration between 
studies (de Grauw et al., 2009; Lucia et al., 2013).  Results from the current study are 
consistent with the previous data that reported synovial CPII values in mature horses to 
be two times greater than young horses.  In the current study peak CPII values (4,886.74 
± 435.74 ng/mL) at 24 h in mature horses are approximately two times greater than those 
observed at 24 h for yearling and 2/3 yr old horses (2,046.67 ± 455.35 ng/mL and 
1901.20 ± 426.08 ng/mL, respectively), indicating increased synthesis of the type II 
collagen component of articular cartilage in mature horses. 
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A metabolic shift toward re-synthesis serves to mend damage to the cartilage 
framework after exposure to inflammatory mediators and deleterious enzymes.  While 
articular cartilage repair involves replacement of the damaged matrix, the tissue does not 
necessarily return to its original structure or function (Frisbie, 2006).  Newly synthesized 
matrix molecules are often damaged, compromising any effective attempts at cartilage 
matrix repair (Poole et al., 2002).  Matrix turnover in mature horses is slow and in young 
individuals metabolism is sustained at a higher level to allow for growth and remodeling 
(Brama et al., 1998).  In the current study ratios of CPII to C2C showed a shift toward 
re-synthesis in both the young and the mature equine model, which, for young horses, 
correlates with results by Lucia et al. (2013).  In the current study, mature horses showed 
increased ability for articular cartilage repair over young horses, possibly because the 
amount of degradation in these horses was higher overall.  This elevated ability towards 
re-synthesis in mature horses may also be accompanied by increased damage to matrix 
molecules shown to be important for the integrity of the joint and its ability to function.  
The results in the current study were surprising, however values for mature horses did 
peak at 336 h, later than younger horses at 168 h, possibly indicating the slower turnover 
rate in mature horses compared to young horses.  Therefore, the current study suggests 
that mature horses may have an increased ability to re-synthesize cartilage in response to 
inflammation and enzymatic breakdown when compared to younger horses, however the 
process takes longer and may be accompanied by increased damage to newly 
synthesized matrix molecules.  Further studies are needed to clarify this relationship 
between horses of varying age.  
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CHAPTER VI 
SUMMARY 
 
Although OA is believed to exist primarily in the aged horse, the disease is 
thought to result from cartilage damage that may develop when training occurs early in 
life. Results from this study indicate an increasing inflammatory response with age in 
horses.  This increased inflammation is accompanied by greater amounts of cartilage 
degradation and repair and, likely, greater amounts of damage in the newly synthesized 
cartilage.  Additionally, with age, the rate of cartilage re-synthesis decreases.  After a 
single inflammatory insult, this decreased rate does not appear to limit the ability of the 
mature horse to repair damaged cartilage.  However, it is possible that without an 
adequate rest period, the older equine athlete returning to work may not have time to 
sufficiently complete the cartilage repair process.  Therefore, further studies are needed, 
to confirm the effects of age on inflammation and cartilage metabolism in exercising 
horses exposed to chronic joint inflammation.   
  
  57 
LITERATURE CITED 
 
Bertone, A. L., J. L. Palmer, and J. Jones. 2001. Synovial fluid cytokines and 
eicosanoids as markers of joint disease in horses. Vet. Surg. 30:528-538. 
Billinghurst, R. C., L. Dahlberg, M. Ionescu, A. Reiner, R. Bourne, C. Rorabeck, P. 
Mitchell, J. Hambor, O. Diekmann, H. Tschesche, J. Chen, H. van Wart, and A. 
R. Poole. 1997. Enhanced cleavage of type II collagen by collagenases in 
osteoarthritic articular cartilage.  J. Clin. Invest. 99:1534-1545. 
Brama, P. J., J. M. TeKoppele, R. A. Bank, A. Barneveld and P. R. van Weeren. 2000. 
Functional adaptation of regional biochemical characteristics up to age one year. 
Equine Vet. J. 32:217-221.  
Brama, P. J., J. M. TeKoppele, R. A. Bank, P. R. van Weeren, and A. Barneveld. 1999. 
Influence of site and age on biochemical characteristics of the collagen network 
of equine articular cartilage. Am. J. Vet. Res. 60:341-345.  
Brama, P. J., J. M. TeKoppele, B. Beekman, P. R. van Weeren, and A. Barneveld. 1998. 
Matrix metalloproteinase activity in equine synovial fluid: influence of age, 
osteoarthritis, and osteochondrosis. Ann. Rheum. Dis. 57:697-699.  
Briston, L., J. Dudhua, and P. Lees. 2009. Age-related differences in prostaglandin E2 
synthesis by equine cartilage explants and synoviocytes. J. Vet. Pharmacol. 
Therap. 33:268-276. 
  58 
Caron, J. P. 1996. Neurogenic factors in joint pain and disease pathogenesis. In: C. W. 
McIlwraith, and G. W. Trotter, editors, Joint disease in the horse. W. B. 
Saunders, Philadelphia, PA. p. 70-80.  
Caron, J. P. and D. H. Genovese. 2003. Principles and practices of joint disease 
treatment. In: M. W. Ross, and S. J. Dyson, editors, Diagnosis and management 
of lameness in the horse. Elsevier, Philadelphia, PA. p. 746-764.  
Caron, J. P., R. M Bowker, R. H. Abhold, D. S. Toppin, I. M. Sonea, and K. B. Vex. 
1992. Substance P in the synovial membrane and fluid of the equine middle 
carpal joint. Equine Vet. J. 24:364-366. 
Chu, Q., M. Lopez, K. Hayashi, M. Ionescu, R. C. Billinghurst, K. A. Johnson, A. R. 
Poole, and M. D. Markel. 2002. Elevation of a collagenase generated type II 
collagen neoepitope and proteoglycan epitopes in synovial fluid following 
induction of joint instability in the dog.  Osteoarthr. Cartil.. 10:662-669. 
de Grauw, J. C., C. H. van de Lest, and P. R. van Weeren. 2009. Inflammatory mediators 
and cartilage biomarkers in synovial fluid after a single inflammatory insult: a 
longitudinal experimental study. Arth. Res. Ther. 11:R35. 
de Grauw, J. C., C. H. van de Lest, P. R. van Weeren, H. Brommer, and P. J. Brama. 
2006. Arthrogenic lameness of the fetlock: synovial fluid markers of 
inflammation and cartilage turnover in relation to clinical joint pain. Equine Vet. 
J. 38:305-311. 
  59 
Dean, D. D., J. Martel-Pelletier, J. P. Pelletier, D. S. Howell, and J. F. Woessner. 1989. 
Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in 
human osteoarthritic cartilage. J. Clin. Invest. 84:678-685. 
Dijkgraaf, L. C., L. G. Debont, G. Boering, and R. S. Liem. 1995. Normal cartilage 
structure, biochemistry, and metabolism: a review of the literature. J. Oral. 
Maxillofac. Surg. 53:924-929. 
Evans, C. H. 1992. Response of synovium to mechanical injury. In: G. A. M. Finerman, 
and F. R. Noyes, editors, Biology and biomechanics of the traumatized synovial 
joint. American Academy of Orthopedic Surgery, Rosemont, IL, p. 17-26.  
Firth, E. C., T. Wensing, and F. Seyren. 1987. An induced synovitis disease model in 
ponies. Cornell Vet. 77:107-118.  
Frisbie, D. D. Synovial joint biology and pathobiology. 2006. In: J. A. Auer, and J. A. 
Stick, editors, Equine surgery. Elsevier, St. Louis, MO. p. 10376-1055.  
Frisbie, D. D., F. Al-Sobayil, R. C. Bilinghurst, C. E. Kawcak, and C. W. McIlwraith. 
2008. Changes in synovial fluid and serum biomarkers with exercise and early 
osteoarthritis in horses. Osteoarthr. Cartil. 16:1196-1204.  
Frisbie, D. D., C. S. Ray, M. Ionescu, A. R. Poole, P. L. Chapman, and C. W. 
McIlwraith. 1999. Measurement of the 846 epitope of chondroitin sulfate and of 
carboxy propeptides of type II collagen for diagnosis of osteochondral 
fragmentation in horses. Am. J. Vet. Res. 60:306-309. 
Fubini, S. L., C. Boatwright, R. J. Todhunter, and G. Lust. 1993. Effect of 
intramuscularly administered polysulfated glycosaminoglycan on articular 
  60 
cartilage from equine joints injected with methylprednisolone acetate. Am. J. 
Vet. Res. 54:1359-1365.  
Garvican, E. R., A. Vaughn-Thomas, J. F. Innes, and P. D. Clegg. 2010. Biomarkers of 
cartilage turnover. Part 1: markers of collagen degradation and synthesis. Vet. J. 
185:36-42. 
Gibson, K. T., H. Hodge, and T. Whittem. 1996. Inflammatory mediators in equine 
synovial fluid. Aust. Vet. J. 73:148-151. 
Goodrich, L. R., and A. J. Nixon. 2006. Medical treatment of osteoarthritis in the horse-a 
review. Vet. J. 171:51-69. 
Gore, T., P. Gore, and J. M. Giffin.  2008.  Normal physiological data.  In: B. Adelman, 
editor, Horse owner’s veterinary handbook.  Wiley Publishing, Inc., Hoboken, 
NJ.  p. 619-624.  
Gustafson, S. B., G. W. Trotter, R. W. Norrdin, R. H. Wrigley, and C. Lamar. 1992. 
Evaluation of intra-articularly administered sodium monoiodoacetate-induced 
chemical injury to articular cartilage of horses. Am. J. Vet. Res. 53:1193-1202.  
Hawkins, D. L., R. J. MacKay, G. G. Gun, P. T. Colahan, and J. C. Meyer. 1993. Effects 
of intra-articularly administered endotoxin on clinical signs of disease and 
synovial fluid tumor necrosis factor, interleukin 6, and prostaglandin E2 values in 
horses. Am. J. Vet. Res. 54: 379-386.  
Hinz, B., and K. Brune. 2004. Pain and osteoarthritis: new drugs and mechanisms. Curr. 
Opin. Rheumatol. 16:628-633. 
Hollander, A. H., T. F. Heathfield, C. Webber, Y. Iwata, R. Bourne, C. Rorabeck, and A. 
  61 
R. Poole. 1994. Increased damage to type II collagen in osteoarthritic articular 
cartilage detected by a new immunoassay. J. Clin. Invest. 93:1722-1732. 
Hurtig, M. B. 1988. Use of autogenous cartilage particles to create a model of naturally 
occurring degenerative joint disease in the horse. Equine Vet. J. 6:19-22.  
Igarashi, M. and Y. Hayashi. 1980. Aging of in vivo cartilage cell. Adv. Expt. Med. 
Biol. 129:111-122. 
Jouglin, M., C. Robert, J. P. Valette, F. Gavard, F. Quintin-Colonna, and J. M. Denoix.  
2000. Metalloproteinases and tumor necrosis factor-alpha activities in synovial 
fluid of horses, correlation with articular cartilage alterations. Vet. Res. 31:507-
515.  
Kempson, G. E. 1980. The mechanical properties of articular cartilage.  In: L. Sokoloff, 
editor, The joints and synovial fluid, volume II.  Academic Press, New York, 
NY. p. 177-238. 
Kidd, J. A., C. Fuller, and A. R. S. Barr. 2001. Osteoarthritis in the horse. Equine Vet. 
Edu. 13:160-168. 
Kirker-Head, C. A., V. K. Chandna, R. K. Agarwal, E. A. Morris, A. Tidwell, M. O. 
O’Callaghan, W. Rand, and S. A. Kumar. 2000. Concentrations of substance P 
and prostaglandin E2 in synovial fluid of normal and abnormal joints of horses. 
Am. J. Vet. Res. 61:714-718. 
Kojima, T., F. Mwale, T. Yasuda, C. Girad, A. R. Poole, and S. Laverty. 2001. Early 
degradation of type IX and type II collagen with the onset of experimental 
inflammatory arthritis. Arthritis Rheum. 44:120-127. 
  62 
Little, C. B., and P. Ghosh. 1997. Variation in proteoglycan metabolism by articular 
chondrocytes in different joint regions is determined by post-natal mechanical 
loading. Osteoarthr. Cartil. 5:49-62. 
Lucia, J. L., J. A. Coverdale, C. E. Arnold, and K. N Winsco. 2013. Influence of an 
intra-articular lipopolysaccharide challenge on markers of inflammation and 
cartilage metabolism in young horses. J. Anim. Sci. 91:2693-2699. 
MacDonald, M. H., S. M. Stover, N. H. Willits, and H. P. Benton. 1994. Regulation of 
matrix metabolism in equine cartilage explant cultures by interleukin 1. Am. J. 
Vet. Res. 53:2278-2285. 
Maroudas, A., G. Palla, and E. Gilav. 1992. Racemization of aspartic acid in human 
articular cartilage. Connect. Tissue Res. 28:161-169.  
Matyas, J. R., L. Atley, M. Ionescu, D. R. Eyre, and A. R. Poole. 2004. Analysis of 
cartilage biomarkers in the early phases of canine experimental osteoarthritis.  
Arthritis Rheum. 50:543-552.  
May, S. A., R. E. Hooke, and P. Lees. 1994a. Interleukin-1 stimulation of equine 
articular cells. Res. Vet. Sci. 52:342-348. 
May, S. A., R. E. Hooke, K. Y. Peremans, F. Verschooten, and P. Lees. 1994b. 
Prostaglandin E2 in equine joint disease. Tijdschr. Diergeneeskd. 63:187-191.   
McIlwraith, C. W. 2002. Diseases of joints, tendons, ligaments, and related structures. 
In: T. S. Stashak, editor, Adams’ lameness in horses. Lea and Febiger, 
Philadelphia, PA. p. 459-644.  
  63 
McIlwraith, C. W. 2005. Use of synovial fluid and serum biomarkers in equine bone and 
joint disease: a review. Equine Vet. J. 37:473-482. 
Meulyzer, M., P. Vachon, F. Beaudry, T. Vinardell, H. Richard, G. Beauchamp, and S. 
Laverty. 2009. Joint inflammation increases glucosamine levels attained in 
synovial fluid following oral administration of glucosamine hydrochloride. 
Osteoarthr. Cartil. 17:228-234. 
Morris, D. D. 1991. Endotoxemia in horses: a review of cellular and humoral mediators 
involved in its pathogenesis. J. Vet. Internal Med. 5:167-181.  
Morris, E. A., S. Wilcox, and B. V. Treadwell. 1992. Inhibition of interleukin-1 
mediated proteoglycan degradation in bovine articular cartilage explants by 
addition of sodium hyaluronate. Am. J. Vet. Res. 53:1977-1982. 
Neil, K. M., J. P. Caron, and M. W. Orth. 2005. The role of glucosamine and chondroitin 
sulfate in treatment for and prevention of osteoarthritis in animals. J. Am. Vet. 
Med. Assoc. 226:1079-1088. 
Palmer, J. L., and A. L. Bertone. 1994a. Experimentally-induced synovitis as a model for 
acute synovitis in the horse. Equine Vet. J. 26:492-495.  
Palmer, J. L., and A. L. Bertone. 1994b. Review article. Joint structure, biochemistry and 
biochemical disequilibrium in synovitis and equine joint disease. Equine Vet. J. 
26:263-277. 
Palmer, J. L., and A. L. Bertone. 1996. Joint biomechanics in the pathogenesis of 
traumatic arthritis. In: C. W. McIlwraith and G. W. Trotter, editors, Joint disease 
in the horse. W.B. Saunders Co., Philadelphia, PA. p. 104-119. 
  64 
Palmer, J. L., A. L. Bertone, and H. McClain. 1995. Assessment of glycosaminoglycan 
concentration in equine synovial fluid as a marker of joint disease.  Can. J. Vet. 
Res. 59:205-212. 
Platt, D. 1996. Articular cartilage homeostasis and the role of growth factors and 
cytokines in regulating matrix composition. In: C. W. McIlwraith and G. W. 
Trotter, editors, Joint disease in the horse. W.B. Saunders Co., Philadelphia, PA. 
p. 29-40. 
Poole, A. R., M. Kobayashi, T. Yasuda, S. Laverty, F. Mwale, T. Kojima, T. Sakai, C. 
Wahl, S. El-Maadawy, G. Webb. E. Tchetina, and W. Wu. 2002. Type II 
collagen degradation and its regulation in articular cartilage in osteoarthritis. 
Ann. Rheum. Dis. 61:ii78-ii81.   
Raetz, C. R. H., R. T. Ulevitch, S. D. Wright, C. H. Sibley, A. Ding, and C. F. Nathan.  
1991. Gram-negative endotoxin: An extraordinary lipid with profound effects on 
eukaryotic signal transduction. FASEB. 5:2652-2660.  
Ray, C. S., A. R. Poole, and C.W. McIlwraith. 1996. Use of synovial fluid and serum 
biomarkers in articular disease. In: C. W. McIlwraith and G. W. Trotter, editors, 
Joint disease in the horse. W.B. Saunders Co., Philadelphia, PA. p. 203-216. 
Schaible, H. G., A. Ebersberger, and G. S. Von Banchet. 2002. Mechanisms of pain in 
arthritis. Ann. N. Y. Acad. Sci. 966:343-354.  
Stockwell, R.A. 1971. The interrelationship of cell density and cartilage thickness in 
mammalian articular cartilage. J. Anat. 109:411-421. 
  65 
Todhunter, R. J. 1996. Anatomy and physiology of synovial joints. In: C. W. McIlwraith 
and G. W. Trotter, editors, Joint disease in the horse. W.B. Saunders Co., 
Philadelphia, PA. p. 1-28. 
Todhunter, R. J., and G. Lust. 1990. Pathophysiology of synovitis: clinical signs and 
examinations in horses. Compend. Contin. Educ. Practicing Vet. 26:980–992. 
Trumble, T. N., A. B. Scarbrough, and M. P. Brown. 2009. Osteochondral injury 
increases type II collagen degradation products (C2C) in synovial fluid of 
Thoroughbred racehorses.  Osteoarthr. Cartil. 17:371-374.    
van den Boom, R., M. R. van de Harst, H. Brommer, P. A. J. Brama, A. Barneveld, P. R. 
van Weeren, and J. DeGroot.  2005a.  Relationship between synovial fluid levels 
of glycosaminoglycans, hydroxyproline and general MMP activity and the 
presence and severity of articular cartilage change on the proximal articular 
surface of P1. Equine Vet. J. 37:19-25.   
van den Boom, R., C. H. van de Lest, S. Bull, R. A. Brama, P. R. van Weeren, and A. 
Barneveld. 2005b. Influence of repeated arthrocentesis and exercise on synovial 
fluid concentrations of nitric oxide, prostaglandin E2 and glycosaminoglycans in 
healthy equine joints. Equine Vet. J. 37:250–256. 
  
  66 
APPENDIX 
ELISA KIT PROTOCOLS 
 
PGE2  (R&D Systems, Minneapolis, MN)  
Synovial fluid samples were analyzed to determine concentrations of PGE2 using 
commercial ELISA kits (R&D Systems, Minneapolis, MN) previously validated for use 
in horses (Bertone et al., 2001; de Grauw et al., 2006).  Synovial fluid samples required a 
1:1.5, 1:2, 1:3, 1:4 or 1:5 dilution, depending on time post-injection using the calibrator 
diluent provided in the kit.  The mean minimum detectable dose was 30.9 pg/mL.  The 
interassay coefficient of variation (cv) averaged 10.6% and the mean intraassay cv was 
6.7%.  
First, 200 μL calibrator diluent was added to the non-specific binding (NSB) 
wells and 150 μL to the zero standard (B0) wells.  Approximately 150 μL of standard or 
sample were then added to all remaining wells.  The NSB, B0, samples and standards 
were all run in duplicate.  Next, 50 μL of primary mouse monoclonal antibody solution 
was added to all wells excluding the NSB wells.  The covered ELISA plate was then 
incubated at room temperature for 1 h on a horizontal orbital microplate shaker (VWR 
Microplate Shaker 120 V, Henry Troemner, LLC, Thorofare, NJ) at 525 rpm.  
Approximately 50 μL of PGE2 conjugated to horseradish peroxidase was added to each 
well.  The covered plate was then incubated for 2 h at room temperature on the shaker at 
525 rpm.  The plate was washed (Labsystems Wellwash 4, Thermo Fisher Sci, Waltham, 
MA) 4 times and blotted after the final wash.  Substrate solution (200 μL) was added to 
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each well and the plate was incubated for another 30 min at room temperature, protected 
from light.  Stop solution (100 μL) was added to each well, changing the color of the 
solution from blue to yellow. The optical density (OD) was determined within 30 min of 
the final incubation using a microplate reader (BioRad 680 Microplate Reader, BioRad 
Laboratories, Hercules, CA) set to 450 nm.  The OD is inversely proportional to the 
amount of PGE2 that is present in the samples.   
 
Catabolic C2C (IBEX Pharmaceuticals Inc., Quebec, Montreal, Canada) 
A commercially available ELISA kit (IBEX Pharmaceuticals Inc., Quebec, 
Montreal, Canada), previously validated for use in horses (Billinghurst et al., 2001; 
Frisbie et al., 2008), was used to measure concentrations of synovial C2C.  Standards 
were diluted following kit recommendations, and samples were diluted at a 1:4 or a 1:5 
dilution, depending on time post-injection.  Samples and standards were diluted using an 
assay buffer solution provided by the manufacturer.  The minimum detectable dose for 
C2C was 10 ng/mL.  The interassay cv averaged 2.9% and the average intraassay cv was 
4.8%.   
Sample (50 μL) was then added to a polypropylene mixing plate followed by the 
addition of 50 μL of C2C antibody diluted in assay buffer.  The mixing plate was pre-
incubated on the plate shaker for 30 min at room temperature (20 to 25°C) at 650 rpm.  
All C2C incubations were performed at room temperature at 650 rpm.  Approximately 
80μL of the antigen-antibody mixture was then transferred to its corresponding well on 
the C2C ELISA plate.  The ELISA plate was then incubated for 1 h, allowing the 
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antibody to bind.  The plate was washed 3 times and blotted dry after the final wash.  
Goat anti-rabbit horseradish peroxidase (GAR-HRP; 100 μL) diluted in assay buffer was 
then added to the plate and incubated for another 30 min.  The ELISA plate was then 
washed 6 times and blotted dry after the final wash.  100 μL tetra-methylbenzidine 
(TMB) buffer warmed to room temperature was added to each well.  The plate was 
incubated again for 30 min and color development was monitored.  The reaction was 
then stopped by the addition of 100 μL stop solution/well, which changed the product 
color from blue to yellow.  Samples were quantified within 10 min of the completion of 
the final incubation using a plate reader set at an OD of 450 nm.  The OD is inversely 
proportional to the amount of C2C that is present in the samples.   
 
Anabolic CPII (IBEX Pharmaceuticals Inc., Quebec, Montreal, Canada) 
A commercially available ELISA kit (IBEX Pharmaceuticals Inc., Quebec, 
Montreal, Canada) with a similar protocol to the C2C ELISA kit was used to measure 
concentrations of synovial CPII.  Samples required a 1:4, 1:5, 1:6 or 1:7 dilution, 
depending on time post-injection and standards were diluted following kit 
recommendations using an assay buffer solution provided with the kit.  The minimum 
detectable dose for CPII was 50 ng/mL.  The interassay cv averaged 3.0% and the mean 
intraassay cv was 4.8%.    
CPII samples and antibody were added to the polypropylene mixing plate 
following the same protocol as the C2C ELISA kit.  The mixing plate was then pre-
incubated for 60 min at 20 to 25°C at 650 rpm.  All CPII incubations were performed at 
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room temperature at 650 rpm.  The CPII antigen-antibody mixture was transferred to the 
CPII ELISA plate using the same methods as the C2C kit.  The CPII ELISA plate was 
covered and allowed to incubate for 2 h.  The ELISA plate was then washed 6 times and 
blotted dry following the final wash.  GAR-HRP was added to each well following the 
same procedure as the C2C kit.  The covered plate was then incubated for 30 min.  The 
plate was then washed another 6 times and blotted dry.  TMB was added to each well 
and a final 30 min incubation was performed.  Color development was monitored and 
stop solution was added.  Samples were quantified using the same plate reader at an OD 
of 450 nm.  The OD is inversely proportional to the amount of CPII that is present in the 
samples.   
 
 
 
 
 
 
 
 
 
 
 
 
 
